TABLE 4.
Cross-tabulation of Oncotype Dx scores and Pathologic stage, and Unadjusted Association With Type of Chemotherapy Among Patients Diagnosed Between 2006 and 2009 Who Were Treated Off Clinical Trial With HER2-Negative and HR-Positive Disease With Oncotype Dx Scores
| T1a, No. (%) |
T1b, No. (%) |
T1c, No. (%) |
Total, No. (%) |
% receiving Intensive Versus non-intensivea |
% receiving TC Versus ACb |
|
|---|---|---|---|---|---|---|
|
|
||||||
| N=3 | N=75 | N=189 | N=268 | |||
| Oncotype Dx recurrence score | ||||||
| Low | 0 | 10 (13) | 24 (13) | 34 (13) | 21 | 58 |
| Intermediate | 3 (100) | 45 (60) | 113 (60) | 161 (61) | 16 | 53 |
| High | 0 | 20 (27) | 50 (27) | 70 (26) | 40 | 39 |
Abbreviations: AC, doxorubicin and cyclophosphamide; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; TC, docetaxel and cyclophosphamide.
There was collinearity between Oncotype Dx recurrence score and grade (high-grade disease was present, respectively, for 26%, 35%, and 66% of patients with low, intermediate, and high scores).
a
P value for trend, <.001.
b
P value for trend, .10.